|
Assessing the Impact of Medicare Reimbursement Changes and Evolving Resistance on the Prevention and Treatment of Hospital-Acquired Infections
— A Webinar from Decision Resources
Based on our 2008 Physician & Payer Forum report, Hospital Anti-Infectives: Insights on the Impact of Medicare Reforms, Formulary Inclusion, and Uptake of Novel Antibiotics and Antifungals, Decision Resources is offering an exclusive, in-depth webinar entitled Assessing the Impact of Medicare Reimbursement Changes and Evolving Resistance on the Prevention and Treatment of Hospital-Acquired Infections. Because this webinar will feature major report findings, it is ONLY available to purchasers of this Physician & Payer Forum report.
Please contact us to learn how you can purchase this Physician & Payer Forum report and attend the webinar.
Following the implementation of the Medicare Hospital-Acquired Conditions Initiative on October 1, 2008, the Centers for Medicare & Medicaid Services has placed restrictions on reimbursement of costs for treating several conditions acquired during hospital stays, including three hospital-acquired infections. Decision Resources has recently surveyed hospital Pharmacy and Therapeutic Committee members, infectious disease specialists and critical care specialists to determine the impact of these changes and other key factors influencing hospital anti-infective prescribing.
Among other topics, this webinar will focus on how recent Medicare reform will affect antibiotic usage, infection control practices, and how drugs are scrutinized for hospital formulary inclusion.
The webinar, presented by Director Danielle Drayton, Ph.D., will answer the following questions:
- According to surveyed hospital committee members, infectious disease specialists and critical care specialists, what impact will the changes in Medicare reimbursement have on medical practice?
- How will prescribing of key antibiotic brands and drug classes change as a result of Medicare reimbursement reform?
- To what extent will infection prevention practices and prescribing controls be affected as hospital committee members, infectious disease specialists and critical care specialists respond to reduced Medicare reimbursement for hospital-acquired infections?
Dr. Drayton and Vice President of Infectious Diseases John Lebbos, M.D. will conduct a live Q&A session after the presentation.
Assessing the Impact of Medicare Reimbursement Changes and Evolving Resistance on the Prevention and Treatment of Hospital-Acquired Infections
November 20, 2008 at 10 a.m. U.S. Eastern Time, 4 p.m. Central European Time (Paris).
For more information, contact Christopher Comfort at ccomfort@dresources.com.
To learn how you can PURCHASE THIS PHYSICIAN & PAYER FORUM REPORT AND ATTEND THIS WEBINAR, please contact:
In North America — Steve Silvestro at 781-296-2626 or ssilvestro@dresources.com
In Europe — Kaj van Langendonck at +32-2-357-06-14 or kvanlangendonck@decisionresources.be
In Japan — Makiko Yoshimoto at +81-3-5401-2615 or makiko@dresources.jp
|
